Geht doch, die Woche ist noch lang, Gruss E.
Geile News von GNBT, bzw bald über 3 Dollar:
Generex Biotechnology Reports Details of Studies Presented At the 2003 American Diabetes Association 63rd Scientific Sessions
TORONTO, Jun 17, 2003 /PRNewswire-FirstCall via COMTEX/ -- Generex
Biotechnology Corporation (Nasdaq: GNBT), a leader in the area of buccal drug
delivery, today reported the details of data from studies sponsored by the
Company and presented at this week's American Diabetes Association conference in
New Orleans, Louisiana. The studies further indicate that the Company's
proprietary Oralin(TM) insulin formulation has the potential to be used safely
and effectively in place of injected insulin to treat patients with Type-1 and
Type-2 diabetes. Oralin(TM) is delivered as a fine spray to the buccal (oral)
cavity via the Company's RapidMist(TM) device, where the formulation is rapidly
absorbed through the buccal mucosal lining.
Reproducibility of Oralin(TM) Absorption in Type-1 Diabetics on 3 Different
Occasions -- The goal of this proof of concept study was to evaluate the
efficacy and the reproducibility of the absorption of the Oralin(TM) spray (10
puffs, no NPH) in Type-1 diabetic patients after a standard meal challenge at
breakfast-time on 3 different occasions. In a randomized crossover study, 12
Type-1 diabetic patients received Oralin(TM) spray via the RapidMist(TM) device
on 3 different occasions 3 to 7 days apart or s.c. injection (8-9 units) with a
360 calories "Ensure" liquid meal 15 minutes after each treatment. The onset
action of Oralin(TM) was much faster and reached its peak level (Tmax) at 20
minutes when compared to s.c. injection (Tmax = 60 minutes). There were no
statically significant differences on 3 different occasions in Oralin(TM)
absorption (p